



**Overview | Demographics**

<b>Because...</b>	<b>We can...</b>
We are 501(c)(3) non-profit with a dual mission of research and education	Empower future generations, through education, to take the best care of their hearts
We are located in the Seattle metro area's Eastside	Recruit from a varied demographic of patients who are supportive of research and protocol-compliant, and who seek a wide variety of cardiovascular therapies

**Experience You Can Count On**

<b>Because...</b>	<b>We can...</b>
100% of our Principal Investigators have 5+ years of research experience	Provide accomplished teams that understand their roles and responsibilities, make themselves accessible, and produce sound judgments
We have 24 physicians on faculty, specializing in cardiology and primary care	Build upon extensive research experience in electrophysiology, interventional and endovascular cardiology, heart failure, hypertension, & diabetes
We employ 3 Research Coordinators with an average of 6 years experience who maintain frequent communication with Principal Investigators, as well as 2 Research Assistants and 1 Regulatory/Contract Administrator	Submit compliant and complete data to sponsors on time, and meet enrollment goals
Our informed, driven, and creative Coordinators are backed by a dedicated Administrative staff	Expedite study start-up activities, allowing the Coordinators to focus on their top priority: patient enrollment and retention

**Facts & Figures | At a Glance**

# of studies   24	# of Active Principal Investigators   9
# of Research Coordinators   3	# of Research Assistants   2
# of Regulatory & Contract staff   1	Endovascular Director   Robert Bersin, MD, FACC
Medical Director   James Leggett, MD, FACC	

**Affiliated Hospitals and Clinics:** Bellevue Cardiology Clinic | Bellevue Heart and Vascular Cascade Heart Clinic, PLLC | Eastside Cardiology Associates | Evergreen Hospital Medical Center Overlake Hospital Medical Center | Overlake Internal Medical Associates | Seattle Cardiology

**Research Study Areas:** Acute Coronary Syndrome | Acute MI | Atrial Fibrillation | Carotid Stenting Coronary Artery Disease & Lipid Therapies | Coronary Stenting | Heart Failure | Hypertension Novel Heart Failure Device Therapies | Pacing & Cardiac Resynchronization Therapy | Renal Artery Disease

**Points of pride in research are highlighted on the next page...**

## Site Performance Examples | Case Studies

- Drug Studies:** The Hope Heart team completes drug studies in a variety of therapeutic areas under the direct supervision of our Principal Investigators. Here is a sample of the kind of work this team can do:*

  - Dr. James Leggett assembled a team of sub-investigators and coordinators for a pivotal phase III open-label trial in acute stenting. Over the course of **13 months**, the team **enrolled 43 patients** with close cooperation from the hospital ER, catheterization lab, and pharmacy. Patients were followed for one year post-procedure. Due to the diligent efforts of the Hope Heart coordinators, only two patients were lost to follow-up (**a 95% retention rate**). Hope Heart administrative staff assisted with a smooth study closeout process.
  - Dr. Thomas Amidon brought together a group of sub-investigators and coordinators for a complex pivotal phase III trial to determine if an investigational drug in combination with an approved drug can slow the progression of coronary atherosclerosis when compared to the approved drug used alone. Changes were measured by intravascular ultrasound (IVUS) performed at the time of enrollment when patients were having a clinically-indicated cardiac catheterization, as compared to an IVUS performed for research two years later. A total of **28 patients were screened with 14 patients ultimately meeting stringent criteria** for randomization. Dr. Amidon and his research staff **successfully retained 12 of the 14 patients through a long, complex protocol** culminating with an end-of-study visit requiring an in-patient hospital admission with cardiac catheterization.
- Device Studies:** The Hope Heart team has been involved in studies to investigate a wide variety of devices - drug-eluting stents, pacemakers, cardiac resynchronization devices, implantable device leads, and novel heart failure devices. Much of our recent work has been in the realm of registries, and we've had impressive results with enrollment and retention.*

REGISTRY	Device Type	Enrollment Duration	Patients Enrolled	Follow-up Duration	Retention Rate
Arrive I	Coronary DES	1.5 months	43	2 years	98%
Ecypher	Coronary DES	2.5 months	66	1 year	90%
XXXX	CRT device with leads	16 months	77	3 years	82%
Decode	CRT-D device	1.5 months	26	2 years	96%

**CONTACT:**  
**Robyn Williams**  
 Clinical Research Administrative Specialist  
 rwilliams@hopeheart.org | 425.456.8712

